ArticleFish physiology and biochemistry2025
Effects of dietary lipid and phospholipid levels on growth performance, lipid metabolism, and antioxidant capacity of largemouth bass (Micropterus salmoides) larvae.
Article in Fish physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DietaryAnimals : an open access journal from MDPI · 2026Article
- Dietary DHA-Enriched Phosphatidylcholine Enhances Muscle Health and Intestinal Barrier Function by Relieving Apoptosis and Oxidative Stress in Largemouth Bass (Aquaculture nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A 42-day feeding trial was conducted to determine the effects of different lipid and phospholipid (PL) levels on growth performance, fatty acid composition, fat deposition, antioxidant capacity, and liver health of largemouth bass (Micropterus salmoides) larvae. Six diets were designed: 6% lipids and 0% PLs (L6/PL0), 3% lipids and 3% PLs (L6/PL50), 0% lipids and 6% PLs (L6/PL100), 12% lipids and 0% PLs (L12/PL0), 6% lipids and 6% PLs (L12/PL50), and 0% lipids and 12% PLs (L12/PL100). These correspond to gradient designs for PLs replacing 0%, 50%, and 100% lipids at the 6% and 12% lipids levels. Results showed that dietary PL supplementation significantly enhanced body weight gain (BWG) and specific growth rate (SGR), with the highest BWG in L12/PL100. PL supplementation reduced both the hepatosomatic index (HSI) and viscerosomatic index (VSI), with the L6/PL100 having the lowest levels. The PL supplementation efficiently reduced liver fat deposition and neutral lipid/polar lipid ratio. The n-3 polyunsaturated fatty acid content in the polar lipid fraction was significantly higher than that in the neutral lipid fraction. Dietary PL supplement significantly increased hepatopancreatic catalase and glutathione activities and decreased malondialdehyde content in the hepatopancreas. PL supplementation significantly reduced liver triglyceride and total cholesterol levels, with the lowest levels observed in the L6/PL100 and L12/PL100 groups. These findings demonstrate that graded PL replacement (up to 100%) at the 6% lipid level optimized growth, reduced fat deposition, increased antioxidant capacity, and avoided the metabolic burden induced by high fat (12% lipids), enhancing LB larval health.
Indexed as
Identifiers
41123677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.